Ependymoma Stem Cells Are Highly Sensitive to Temozolomide in Vitro and in Orthotopic Models

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2014 Feb 15

PMID 24526307

Citations 15

Authors

Daniela Meco

Tiziana Servidei

Giuseppe Lamorte

Elena Binda

Vincenzo Arena

Riccardo Riccardi

Affiliations

Soon will be listed here.

Abstract

Background: Ependymoma management remains challenging because of the inherent chemoresistance of this tumor. To determine whether ependymoma stem cells (SCs) might contribute to therapy resistance, we investigated the sensitivity of ependymoma SCs to temozolomide and etoposide.

Methods: The efficacies of the two DNA damaging agents were explored in two ependymoma SC lines in vitro and in vivo models.

Results: Ependymoma SC lines were highly sensitive to temozolomide and etoposide in vitro, but only temozolomide impaired tumor-initiation properties. Consistently, temozolomide but not etoposide showed significant antitumoral activity on ependymoma SC-driven subcutaneous and orthotopic xenografts by reducing the mitotic fraction. In vitro temozolomide at the EC50 (10 µM) induced accumulation of cells in the G2/M phase that was unexpectedly accompanied by downregulation of p27 and p21 without modulation of full-length p53 (FLp53). Differentiation-committed ependymoma SCs acquired resistance to temozolomide. Inhibition of proliferation was partly due to apoptosis, that occurred earlier in differentiated cells as compared to neurospheres. The activation of apoptosis correlated with an increase in p53β/γ isoforms without modulation of FLp53 under both serum-free and differentiation-promoting media. Incubation of cells in both conditions with temozolomide resulted in increased glioneuronal differentiation exhibiting elevated glial fibrillary acidic protein, galactosylceramidase, and βIII-tubulin expression compared to untreated controls. O(6)-methylguanine DNA methyltransferase (MGMT) transcript levels were very low in SCs, and were increased by treatment and, epigenetically, by differentiation through MGMT promoter unmethylation.

Conclusion: Ependymoma growth might be impaired by temozolomide through preferential depletion of a less differentiated, more tumorigenic, MGMT-negative cell population with stem-like properties.

Citing Articles

Spinal Ependymomas: An Updated WHO Classification and a Narrative Review.

Villanueva-Castro E, Meraz-Soto J, Hernandez-Dehesa I, Tena-Suck M, Hernandez-Resendiz R, Mateo-Nouel E Cureus. 2023; 15(11):e49086.

PMID: 38125233 PMC: 10731541. DOI: 10.7759/cureus.49086.

Glioma Stem Cells in Pediatric High-Grade Gliomas: From Current Knowledge to Future Perspectives.

Da-Veiga M, Rogister B, Lombard A, Neirinckx V, Piette C Cancers (Basel). 2022; 14(9).

PMID: 35565425 PMC: 9099564. DOI: 10.3390/cancers14092296.

The biology of ependymomas and emerging novel therapies.

Saleh A, Samuel N, Juraschka K, Saleh M, Taylor M, Fehlings M Nat Rev Cancer. 2022; 22(4):208-222.

PMID: 35031778 DOI: 10.1038/s41568-021-00433-2.

Cell-of-Origin and Genetic, Epigenetic, and Microenvironmental Factors Contribute to the Intra-Tumoral Heterogeneity of Pediatric Intracranial Ependymoma.

Servidei T, Lucchetti D, Navarra P, Sgambato A, Riccardi R, Ruggiero A Cancers (Basel). 2021; 13(23).

PMID: 34885210 PMC: 8657076. DOI: 10.3390/cancers13236100.

Clinical Prediction Modeling in Intramedullary Spinal Tumor Surgery.

Massaad E, Ha Y, Shankar G, Shin J Acta Neurochir Suppl. 2021; 134:333-339.

PMID: 34862557 DOI: 10.1007/978-3-030-85292-4_37.

References

Sato A, Sunayama J, Matsuda K, Seino S, Suzuki K, Watanabe E . MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis. Stem Cells. 2011; 29(12):1942-51. DOI: 10.1002/stem.753. View

Koos B, Bender S, Witt H, Mertsch S, Felsberg J, Beschorner R . The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas. Clin Cancer Res. 2011; 17(11):3631-7. DOI: 10.1158/1078-0432.CCR-11-0175. View

Lapenna S, Giordano A . Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009; 8(7):547-66. DOI: 10.1038/nrd2907. View

Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer K . Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res. 2010; 16(10):2715-28. DOI: 10.1158/1078-0432.CCR-09-1800. View

Christmann M, Verbeek B, Roos W, Kaina B . O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim Biophys Acta. 2011; 1816(2):179-90. DOI: 10.1016/j.bbcan.2011.06.002. View

Munoz P, Iliou M, Esteller M . Epigenetic alterations involved in cancer stem cell reprogramming. Mol Oncol. 2012; 6(6):620-36. PMC: 5528346. DOI: 10.1016/j.molonc.2012.10.006. View

Witt H, Mack S, Ryzhova M, Bender S, Sill M, Isserlin R . Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell. 2011; 20(2):143-57. PMC: 4154494. DOI: 10.1016/j.ccr.2011.07.007. View

Weller M, Stupp R, Reifenberger G, Brandes A, van den Bent M, Wick W . MGMT promoter methylation in malignant gliomas: ready for personalized medicine?. Nat Rev Neurol. 2009; 6(1):39-51. DOI: 10.1038/nrneurol.2009.197. View

Bocangel D, Finkelstein S, Clifford Schold S, Bhakat K, Mitra S, Kokkinakis D . Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 2002; 8(8):2725-34. View

10.

Taylor M, Poppleton H, Fuller C, Su X, Liu Y, Jensen P . Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005; 8(4):323-35. DOI: 10.1016/j.ccr.2005.09.001. View

11.

Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C . BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis. 2012; 3:e412. PMC: 3481140. DOI: 10.1038/cddis.2012.153. View

12.

Martinez R, Esteller M . The DNA methylome of glioblastoma multiforme. Neurobiol Dis. 2010; 39(1):40-6. DOI: 10.1016/j.nbd.2009.12.030. View

13.

Roos W, Batista L, Naumann S, Wick W, Weller M, Menck C . Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 2006; 26(2):186-97. DOI: 10.1038/sj.onc.1209785. View

14.

Blough M, Westgate M, Beauchamp D, Kelly J, Stechishin O, Ramirez A . Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol. 2010; 12(7):756-60. PMC: 2940656. DOI: 10.1093/neuonc/noq032. View

15.

Beier D, Rohrl S, Pillai D, Schwarz S, Kunz-Schughart L, Leukel P . Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 2008; 68(14):5706-15. DOI: 10.1158/0008-5472.CAN-07-6878. View

16.

Hadjipanayis C, Van Meir E . Brain cancer propagating cells: biology, genetics and targeted therapies. Trends Mol Med. 2009; 15(11):519-30. PMC: 2782740. DOI: 10.1016/j.molmed.2009.09.003. View

17.

Zucchetti M, Catapano C, Filippeschi S, Erba E, DIncalci M . Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation. Biochem Pharmacol. 1989; 38(13):2069-75. DOI: 10.1016/0006-2952(89)90059-2. View

18.

Tolcher A, Gerson S, Denis L, Geyer C, Hammond L, Patnaik A . Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003; 88(7):1004-11. PMC: 2376384. DOI: 10.1038/sj.bjc.6600827. View

19.

Singh S, Clarke I, Terasaki M, Bonn V, Hawkins C, Squire J . Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18):5821-8. View

20.

Palmisano W, Divine K, Saccomanno G, Gilliland F, Baylin S, Herman J . Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000; 60(21):5954-8. View